Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG2417 in Bipolar I Depression
NCT00812058Phase 2Completed
- Sponsor
- Repligen Corporation
- Start
- Nov 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar I disorder comparing RG2417 with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Nov 2008; status: completed.
02
Drugs
uridine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00812058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00812058.